Keros Therapeutics, Inc. (KROS)
USD 17.13
(-4.83%)
USD 17.13
(-4.83%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -124.5 Million | -70.06 Million | -62.14 Million | -36.89 Million | -15.99 Million | 7.04 Million |
| Net Income | -152.99 Million | -104.67 Million | -58.74 Million | -45.36 Million | -12.33 Million | -1.33 Million |
| Depreciation & Amortization | 815 Thousand | 674 Thousand | 378 Thousand | 278 Thousand | 208 Thousand | 153 Thousand |
| Deferred income taxes | 4000.00 | - | 46 Thousand | - | - | - |
| Stock-based compensation | 28.76 Million | 18.68 Million | 11.72 Million | 4.09 Million | 59 Thousand | 81 Thousand |
| Change in working capital | -2.65 Million | 14.3 Million | -16.07 Million | 2.27 Million | -6.72 Million | 7.94 Million |
| Other non-cash items | 1.55 Million | 953 Thousand | 520 Thousand | 1.81 Million | 2.79 Million | 194 Thousand |
| Investing Cash Flow | -2.46 Million | -1.24 Million | -1.02 Million | -294 Thousand | -271 Thousand | -217 Thousand |
| Investments in PPE | -2.46 Million | -1.24 Million | -1.02 Million | -294 Thousand | -271 Thousand | -217 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 178.95 Million | 120.3 Million | 28.55 Million | 296.04 Million | 14 Thousand | 11.46 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 175.82 Million | 119.57 Million | 28.17 Million | 243.2 Million | 14 Thousand | 11.46 Million |
| Other Financing Activities | 3.13 Million | 731 Thousand | 379 Thousand | 52.84 Million | 14 Thousand | 11.46 Million |
| Accounts receivables | -143 Thousand | 18 Million | -18 Million | 922 Thousand | -552 Thousand | -370 Thousand |
| Accounts payables | 1.61 Million | -408 Thousand | 1.48 Million | 61 Thousand | 1.31 Million | -2000.00 |
| Inventory | -4.5 Million | - | 1.04 Million | -922 Thousand | 552 Thousand | - |
| Other working capital | 384 Thousand | -3.28 Million | -597 Thousand | 2.21 Million | -8.03 Million | 7.95 Million |
| Cash at beginning of period | 280.37 Million | 231.36 Million | 265.99 Million | 7.13 Million | 23.39 Million | 5.1 Million |
| Cash at end of period | 332.35 Million | 280.37 Million | 231.36 Million | 265.99 Million | 7.13 Million | 23.39 Million |
| Capital Expenditure | -2.46 Million | -1.24 Million | -1.02 Million | -294 Thousand | -271 Thousand | -217 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 51.98 Million | 49 Million | -34.62 Million | 258.85 Million | -16.25 Million | 18.28 Million |
| Free Cash Flow | -126.97 Million | -71.3 Million | -63.17 Million | -37.18 Million | -16.26 Million | 6.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -45.25 Million | -43.11 Million | -152.99 Million | -40.24 Million | -39.44 Million | -37.5 Million |
| Depreciation & Amortization | 306 Thousand | 277 Thousand | 815 Thousand | 247 Thousand | 210 Thousand | 191 Thousand |
| Deferred income taxes | - | - | 4000.00 | - | - | - |
| Stock-based compensation | 8.78 Million | 8.07 Million | 28.76 Million | 7.32 Million | 8.71 Million | 7.04 Million |
| Change in working capital | -3.98 Million | -10.13 Million | -2.65 Million | 6.87 Million | -3.8 Million | -913 Thousand |
| Other non-cash items | 7.9 Million | 9.02 Million | 1.55 Million | 335 Thousand | 341 Thousand | 354 Thousand |
| Investing Cash Flow | -310 Thousand | -946 Thousand | -2.46 Million | -541 Thousand | -550 Thousand | -311 Thousand |
| Investments in PPE | -310 Thousand | -946 Thousand | -2.46 Million | -541 Thousand | -550 Thousand | -311 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 3.53 Million | 156.8 Million | 178.95 Million | 69.25 Million | 284 Thousand | 1.74 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.53 Million | 156.8 Million | 175.82 Million | 68.51 Million | 284 Thousand | 1.74 Million |
| Other Financing Activities | -65 Thousand | -259 Thousand | 3.13 Million | 737 Thousand | 284 Thousand | 1.74 Million |
| Accounts receivables | 222 Thousand | -83 Thousand | -143 Thousand | -143 Thousand | - | - |
| Accounts payables | 1.61 Million | 23 Thousand | 1.61 Million | 1.04 Million | -182 Thousand | -570 Thousand |
| Inventory | - | - | -4.5 Million | 5.84 Million | - | - |
| Other working capital | -5.81 Million | -10.07 Million | 384 Thousand | 129 Thousand | -3.62 Million | -343 Thousand |
| Cash at beginning of period | 442.44 Million | 331.14 Million | 280.37 Million | 289.1 Million | 323.35 Million | 352.75 Million |
| Cash at end of period | 405.86 Million | 442.44 Million | 332.35 Million | 332.35 Million | 289.1 Million | 323.35 Million |
| Capital Expenditure | -310 Thousand | -946 Thousand | -2.46 Million | -541 Thousand | -550 Thousand | -311 Thousand |
| Effect of forex changes on cash | - | - | - | - | 46.69 Million | - |
| Net cash flow / Change in cash | -36.58 Million | 111.29 Million | 51.98 Million | 43.25 Million | -34.24 Million | -29.4 Million |
| Free Cash Flow | -40.11 Million | -45.5 Million | -126.97 Million | -26 Million | -34.53 Million | -31.14 Million |
RKNEF
MMTIF
KREVF
UVSE
0II3
TORNTPHARM